Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); Facing Uphill Battle
Tweet Send to a FriendGet Alerts ONXX Hot Sheet
Price: $88.80 --0%
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Rating Summary:
20 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Trade ONXX Now!
Barclays maintains an 'Equalweight' on Onyx Pharmaceuticals (NASDAQ: ONXX) price target raised from $40 to $44.
Analyst, Ying Huang, said, "We continue to believe carfilzomib will face an uphill battle for accelerated approval. Carfilzomib has an upcoming Oncologic Drugs Advisory Committee (ODAC) panel on June 20th, and PDUFA date of July 27th. Based on historical precedent, we believe FDA approval with a single arm Phase II study under standard review is unlikely."
Huang slashes FY12 EPS loss from -1.06 to -2.73 and FY13 from -1.30 to -2.83.
Note - currently shares are trading down $2.26 (-5.02%), which is near the session low.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $45.00 yesterday, with a 52 week range of $27.17-$47.80.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ying Huang, said, "We continue to believe carfilzomib will face an uphill battle for accelerated approval. Carfilzomib has an upcoming Oncologic Drugs Advisory Committee (ODAC) panel on June 20th, and PDUFA date of July 27th. Based on historical precedent, we believe FDA approval with a single arm Phase II study under standard review is unlikely."
Huang slashes FY12 EPS loss from -1.06 to -2.73 and FY13 from -1.30 to -2.83.
Note - currently shares are trading down $2.26 (-5.02%), which is near the session low.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $45.00 yesterday, with a 52 week range of $27.17-$47.80.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Goldman Sachs Upgrades Tanger Factory Outlet Centers (SKT) to Neutral
- UPDATE: Bernstein Cuts BlackBerry (BBRY) to Underperform; Notes Weak BB10 Traction
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
